Can a phone app keep teens on track with sickle cell treatment?

NCT ID NCT04688411

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This pilot trial tests whether a smartphone app called MED-Go can help adolescents and young adults with sickle cell disease take their daily hydroxyurea more consistently. Participants aged 12 to 21 will use the app for 12 weeks, and researchers will measure how often they log their doses and how usable they find the app. The goal is to see if this digital approach is practical and acceptable enough to support better medication habits and, ultimately, better health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MED-Go app, a smartphone application designed to support daily hydroxyurea adherence
What this could lead to
If the app proves practical and user-friendly, it could offer a simple digital tool to help young people with sickle cell disease stay consistent with their medication, potentially improving long-term health.
What could go wrong
This is a small pilot study focused on feasibility, not health outcomes. The app may not be engaging enough for daily use, and any benefit to disease control remains uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE B+ THALASSEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ann & Robert H Lurie Children's Hospital of Chicago

    Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.